Compare Gilead Sciences, Inc. (GILD) vs SpaceX (SPCX) Price & Performance

Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.

Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.

SPCX trades at $134.95, down 0.83% and below its $135 IPO price for the first time. The stock shows bearish technical signals with negative earnings momentum (Q1 2026 EPS miss of -$1.19 vs -$0.33 expected) and widening losses (2026 net profit margin projected at -45%). Despite 100% analyst buy ratings and a $241.50 consensus target, high valuations (P/S 91.64, EV/EBITDA 951.8) and accelerating capital expenditures create significant investor skepticism.

The outlook remains challenged by substantial operational losses and cash burn, though long-term growth potential in space technology offers speculative upside. Key risks include execution on costly projects, competitive pressure, and dependency on future revenue streams to justify current valuation.